Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Trials|June 19, 2019
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapyWesley de Jong, Joeri Aerts, Sabine Allard, et al.
Plos One|April 12, 2012
Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPTRafael Van den Bergh, Sébastien Morin, Hans Jürgen Sass, et al.
Plos One|September 12, 2013
Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination modelLeo Heyndrickx, Guillaume Stewart-Jones, Marianne Jansson, et al.
Journal of Virology|July 5, 2005
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progressionRyan M Troyer, Kalonji R Collins, Awet Abraha, et al.
The Journal of Antimicrobial Chemotherapy|May 7, 2013
Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmissionKevin K Ariën, Muthusamy Venkatraj, Johan Michiels, et al.
Journal of Translational Medicine|July 10, 2013
Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolateMaria Luisa Visciano, Maria Tagliamonte, Guillaume Stewart-Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2009
Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea BissauSabelle Jallow, Tim Vincent, Aleksandra Leligdowicz, et al.
Bioorganic & Medicinal Chemistry|September 21, 2011
Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs)Muthusamy Venkatraj, Kevin K Ariën, Jan Heeres, et al.
Scientific Reports|October 11, 2016
CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challengeKevin K Ariën, Françoise Baleux, Delphine Desjardins, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 15, 2006
Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cellsGlenn A Van den Bosch, Ellen Van Gulck, Peter Ponsaerts, et al.
Pageof 14